Close to 120 companies across the globe claim to possess the required expertise and infrastructure to offer contract manufacturing services for HPAPIs and cytotoxic drugs, claims Roots Analysis

Developmentinitiatives of HPAPIs and cytotoxic drugs are generally very demanding, both interms of experience and capital investment. Most companies generally lack thenecessary resources to meet the aforementioned requirements and are unable toset up dedicated HPAPI and cytotoxic drug manufacturing facilities. This hasled to an increased demand for contract manufacturing service providers in thisfield.

To order this 300+ page report, which features 75+ figuresand 150+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html

The USD 25 billion(by 2030) financial opportunity within the HPAPI and cytotoxic drugs contractmanufacturing market has been analyzed across the following segments:

§  Typeof Product

§  HPAPIs

§  HighlyPotent Finished Dosage Forms

§ Company Size

§ Small-sized

§ Mid-sized

§ Large / Very Large

§  Scaleof Operation

§ Preclinical / Clinical

§ Commercial

§  Typeof Pharmacological Molecule

§ Small Molecules

§ Biologics

§  Typeof Highly Potent Finished Dosage Form

§  Injectables

§  OralSolids

§  Creams

§  Others

§  Keygeographical regions

§  NorthAmerica

§  Europe

§  AsiaPacific

§  Restof the World

The “HPAPIand Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030” report features the following companies, which weidentified to be key players in this domain:

§ AbbVie Contract Manufacturing

§ CARBOGEN AMCIS

§ Catalent

§ Evonik

§ Formosa Laboratories

§ Intas

§ Lonza

§ MabPlex

§ Pfizer CentreOne

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Company Competitive Analysis

6. HPAPI and Cytotoxic Drugs Contract Manufacturers basedin North America: Company Profiles

7. HPAPI and Cytotoxic Drugs Contract Manufacturers basedin Europe: Company Profiles

8. HPAPI and Cytotoxic Drugs Contract Manufacturers basedin Asia Pacific: Company Profiles

9. Partnerships and Collaborations

10. Recent Expansions

11. Capacity Analysis

12. Market Sizing and Opportunity Analysis

13. Case-In-Point: Contract Manufacturing of Antibody DrugConjugates

14. Concluding Remarks

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html  

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com